You are here

Structural Heart

 

After one month, patients with severe aortic stenosis and intermediate surgical risk had improved health status if they underwent transcatheter aortic valve replacement (TAVR) rather than surgical aortic valve replacement (SAVR), according to an analysis of a randomized study. The analysis also found that patients in both groups had similar quality of life outcomes at two years.

For this issue, we gave cardiologists a crystal ball, figuratively, of course, and asked them what they saw for their specialty’s future.

David J. Cohen, MD, MSc, and the chief medical officers of three stent companies discuss stents, strategy and the future of healthcare.

SCAI examines the implications of the FDA’s decision to expand the TAVR indication to include patients at intermediate risk for SAVR.

A new transcatheter aortic valve implantation (TAVI) by Boston Scientific has received market approval in Europe.

 

Recent Headlines

College football linemen at increased risk of hypertension

Changes in blood pressure and thickening of the heart walls are seen more often in this specific position. 

Swollen joints, anti-inflammatories are hard on the heart

The anti-inflammatory drugs used by osteoarthritis and rheumatoid arthritis patients could be increasing risks of cardiovascular disease (CVD).

Well-fed mothers produce babies with healthy hearts

Prenatal care is vital to the future health of a baby. It’s important for expecting mothers to stop smoking and drinking alcohol and to increase their folic acid intake. But in addition to these steps, mothers must also maintain a healthy weight.

TCT 2016: Sapien valve is durable up to 5 years in patients with severe aortic stenosis

Patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) with the Sapien first generation device had positive hemodynamics up to five years following implant, according to an analysis of a randomized trial.

TCT 2016: Quality of life at two years is similar for TAVR, SAVR patients

After one month, patients with severe aortic stenosis and intermediate surgical risk had improved health status if they underwent transcatheter aortic valve replacement (TAVR) rather than surgical aortic valve replacement (SAVR), according to an analysis of a randomized study. The analysis also found that patients in both groups had similar quality of life outcomes at two years.

If You Give a Cardiologist a Crystal Ball

For this issue, we gave cardiologists a crystal ball, figuratively, of course, and asked them what they saw for their specialty’s future.

FDA expands approval for Medtronic’s CoreValve Evolut R system in larger size

The FDA approved Medtronic’s CoreValve Evolut R system in a new 34 mm size valve for patients undergoing transcatheter aortic valve replacement (TAVR).

Stents + Sensibility: Talking Technology + Trends with Cardiology Device Makers

David J. Cohen, MD, MSc, and the chief medical officers of three stent companies discuss stents, strategy and the future of healthcare.

Preparing for the Flood: Expanded TAVR Indication Comes with Challenges

SCAI examines the implications of the FDA’s decision to expand the TAVR indication to include patients at intermediate risk for SAVR.

Parasitic heart disease threat creeps into U.S.

Chagas heart disease is common in Latin America. Now, given the growing immigrant population, U.S. physicians need to know how to recognize and treat it. 

Pages